Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological processes including cell division, cell quiescence and inflammation. It has been shown that AHR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, loss of AHR in knockout mice is accompanied by a myeloproliferative syndrome-like disease, suggesting a role of AHR in hematopoietic stem cell (HSC) maintenance. To study the potential role of AHR pathway in CML progenitors and stem cells, we have first evaluated the expression of AHR in UT-7 cell line expressing BCR-ABL. AHR expression was highly reduced in UT-7 cell expressing BCR-ABL as compared to controls. AHR transcript levels, quantified in primary peripheral blood CML cells at diagnosis (n = 31 patients) were found to be significantly reduced compared to healthy controls (n = 15). The use of StemRegenin (SR1), an AHR antagonist, induced a marked expansion of total leukemic cells and leukemic CD34+ cells by about 4- and 10-fold respectively. SR1-treated CML CD34+ cells generated more colony-forming cells and long-term culture initiating cell (LTC-IC)–derived progenitors as compared to non-SR1-treated counterparts. Conversely, treatment of CML CD34+ cells with FICZ, a natural agonist of AHR, induced a 3-fold decrease in the number of CD34+ cells in culture after 7 days. Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. Similarly, a 3-day FICZ treatment contributed to hinder significantly the number of LTC-IC-derived progenitors without synergistic effect with Imatinib. The analysis of molecular circuitry of AHR signaling in CML showed a transcriptional signature in CML derived CD34+ CD38- primitive cells with either low or high levels of AHR, with an upregulation of myeloid genes involved in differentiation in the “AHR low” fraction and an upregulation of genes involved in stem cell maintenance in the “AHR high” fraction. In conclusion, these findings demonstrate for the first time that down-regulation of AHR expression, a major cell cycle regulator, is involved in the myeloproliferative phenotype associated with CML. AHR agonists inhibit clonogenic and LTC-IC-derived progenitor growth and they could be used in leukemic stem cell targeting in CML.
AhR is an ubiquitous basic helix-loop-helix protein, mediating cell responses to external ligands and involved in cell division, cell quiescence and inflammatory responses. After ligand binding, AhR, which is an intracytoplasmic receptor associated to HSP60, dissociates from it and translocates to nucleus where it binds to aryl hydrocarbon nuclear translator (ARNT), this dimeric complex activating transcription. It has been shown that AhR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, AhR K/O mice exhibit a myeloproliferative syndrome-like disease, suggesting a role of AhR in hematopoietic stem cell (HSC) quiescence. The goal of this study was to study the potential role of AhR and its partners in CML progenitors and stem cells. We have first evaluated the expression of AhR in UT7 cell line and UT7-cells expressing BCR-ABL. AhR expression was highly reduced in UT7 cell expressing BCR-ABL as compared to control. AhR transcript was then quantified in primary peripheral blood CML cells at diagnosis (n=31 patients) and were found to be very significantly reduced as compared to normal controls (n=15) (p < 0.05). In 8 of these patients, AhR mRNA was quantified during TKI-induced major molecular response (MMR) and were found to increase towards levels found in controls. To determine if AhR expression is differentially expressed in HSC as compared to progenitors, we have analyzed AhR expression in CD34+ cells (n=11) as well as in highly purified CD34+ CD38- cell populations (n=3). Interestingly, AhR expression was reduced in leukemic CD34+ progenitors (n=11) but not in more primitive leukemic CD34+ CD38- cells (n=3) as compared to normal controls (n=15). These data suggested that AhR, known to be involved in HSC quiescence, could be amenable to pharmacological manipulation in CML cells. We first evaluated the potential effects of StemRegenin (SR1), which is an AhR antagonist on the growth of leukemic progenitors and stem cells. CD34+ CML cells treated with SR-1 had a reduced expression of AHHR, a repressor of AhR. In 7-day liquid cultures, the use of SR-1 at 0.75 µM induced a major expansion of leukemic cells by 60-fold as compared to conditions without SR-1 (p < 0.05). Similarly, SR-1 allowed expansion of leukemic CD34+ cells by 6-fold in 7 days, as compared to controls. CD34+ cells expanded in SR-1, were then used in CFC and LTC-IC assays to determine if SR-1 could allow maintenance and/or expansion of CML progenitors and stem cells. CML CD34+ cells cultured with SR-1 for 7 and 14 days exhibited a massive expansion of leukemic CFC (> 3 fold increase). Similarly, CD34+ cells expanded with SR-1 for 4 and 7 days followed by long-term culture initiating cells (LTC-IC) assays, revealed a massive expansion ( > 10-Fold) of LTC-IC-derived progenitors. We then used the 6-Formylindolo (3,2-b) carbazole (FICZ), a natural agonist of AhR, to determine its effects on leukemic progenitors and stem cells. The agonistic effect of FICZ was validated by the increase of the downstream target of AHR CYP1A1 transcripts after 7 days of culture. As expected, liquid culture of CML CD34+ cells induced a 2-fold decrease of CD34+ cells at day+7 in the presence of 100 nM of FICZ. Day-4 FICZ cultured CD34+ cells showed a significant reduction of leukemic CFC potential with a synergistic profile with Imatinib and Dasatinib ( p < 0.05). Similarly, in three patients, in LTC-IC assays started after 3-day FICZ-treated cells, 5-week LTC-IC-derived progenitors showed a significant growth inhibition with a synergistic profile with Imatinib. In conclusion, these findings demonstrate for the first time that down-regulation of AhR expression, a major cell cycle regulator, is involved in the MPD phenotype associated with CML. The further inhibition of AhR expression by its antagonist allowed massive expansion of hematopoietic progenitors and stem cells. In contrast, AhR agonists inhibit clonogenic and LTC-IC-derived stem cell growth and could be used in LSC targeting in CML. Disclosures Turhan: Bristol Myers Squibb: Consultancy; Novartis: Research Funding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.